Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy

অনুরূপ উপাদানগুলি

• Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''
  অনুযায়ী: Fujii, Takeo, অন্যান্য
  প্রকাশিত: (2017)
• Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab
  অনুযায়ী: Kogawa, Takahiro, অন্যান্য
  প্রকাশিত: (2020)
• High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer
  অনুযায়ী: Kogawa, Takahiro, অন্যান্য
  প্রকাশিত: (2016)
• The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
  অনুযায়ী: Chainitikun, Sudpreeda, অন্যান্য
  প্রকাশিত: (2020)
• Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy
  অনুযায়ী: Wong, Yao, অন্যান্য
  প্রকাশিত: (2018)